BACKGROUND: Inhaled corticosteroids have been widely reported as a preventive measure against the development of severe forms of COVID-19 not only in patients with asthma. METHODS: In 654 Czech and Slovak patients with asthma who developed COVID-19, we investigated whether the correct use of inhaler containing corticosteroids was associated with a less severe course of COVID-19 and whether this had an impact on the need for hospitalisation, measurable lung functions and quality of life (QoL). RESULTS: Of the studied cohort 51.4% had moderate persistent, 29.9% mild persistent and 7.2% severe persistent asthma. We found a significant adverse effect of poor inhaler adherence on COVID-19 severity (p=0.049). We also observed a lower hospitalisation rate in patients adequately taking the inhaler with OR of 0.83. Vital capacity and forced expiratory lung volume deterioration caused by COVID-19 were significantly reversed, by approximately twofold to threefold, in individuals who inhaled correctly. CONCLUSION: Higher quality of inhalation technique of corticosteroids measured by adherence to an inhaled medication application technique (A-AppIT) score had a significant positive effect on reversal of the vital capacity and forced expiratory lung volume in 1 s worsening (p=0.027 and p<0.0001, respectively) due to COVID-19. Scoring higher in the A-AppIT was also associated with significantly improved QoL. All measured variables concordantly and without exception showed a positive improvement in response to better adherence. We suggest that corticosteroids provide protection against the worsening of lungs in patients with COVID-19 and that correct and easily assessable adherence to corticosteroids with appropriate inhalation technique play an important role in preventing severe form of COVID-19.

CEEOR spol s r o Prague Czech Republic

Department of Biomedical Technology Czech Technical University Prague Faculty of Biomedical Engineering Kladno Czech Republic

Department of Pulmonology and Phthisiology Comenius University in Bratislava Jessenius Faculty of Medicine in Martin Martin Slovakia

Department of Respiratory Medicine Fakultní Nemocnice Hradec Králové Hradec Králové Czech Republic

Faculty of Health Catholic University in Ruzomberok Ruzomberok Slovakia

National Institute of Tuberculosis Lung Diseases and Thoracic Surgery Vyšné Hágy Slovakia Vyšné Hágy Slovakia Vyšné Hágy Slovakia

Zobrazit více v PubMed

COVID-19 National Preparedness Collaborators . Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. Lancet 2022;399:1489–512. 10.1016/S0140-6736(22)00172-6 PubMed DOI PMC

Merad M, Blish CA, Sallusto F, et al. . The immunology and immunopathology of COVID-19. Science 2022;375:1122–7. 10.1126/science.abm8108 PubMed DOI

Bartoletti M, Azap O, Barac A, et al. . ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect 2022;28:222–38. 10.1016/j.cmi.2021.11.007 PubMed DOI PMC

Sahu AK, Mathew R, Bhat R, et al. . Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis. QJM 2021;114:455–63. 10.1093/qjmed/hcab212 PubMed DOI

Reddel HK, Bacharier LB, Bateman ED, et al. . Global initiative for asthma strategy 2021 executive summary and rationale for key changes. Am J Respir Crit Care Med 2022;205:17–35. 10.1164/rccm.202109-2205PP PubMed DOI PMC

Cloutier MM, Dixon AE, Krishnan JA, et al. . Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program. JAMA 2020;324:2301–17. 10.1001/jama.2020.21974 PubMed DOI

Kwah JH, Peters AT. Asthma in adults: principles of treatment. Allergy Asthma Proc 2019;40:396–402. 10.2500/aap.2019.40.4256 PubMed DOI

Venkatesan P. GINA report for asthma. Lancet Respir Med 2023;11:589. 10.1016/S2213-2600(23)00230-8 PubMed DOI

Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes Allergy 2020;75:1543–5. 10.1111/all.14348 PubMed DOI PMC

Bloom CI, Drake TM, Docherty AB, et al. . Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO clinical characterisation protocol UK. Lancet Respir Med 2021;9:699–711. 10.1016/S2213-2600(21)00013-8 PubMed DOI PMC

Lipworth B, Chan R, Kuo CRW. Use of inhaled corticosteroids in asthma and Coronavirus disease 2019: keep calm and carry on. Ann Allergy Asthma Immunol 2020;125:503–4. 10.1016/j.anai.2020.06.026 PubMed DOI PMC

Suda K, Tsuruta M, Eom J, et al. . Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. Am J Respir Cell Mol Biol 2011;45:510–6. 10.1165/rcmb.2010-0169OC PubMed DOI

Yamaya M, Nishimura H, Deng X, et al. . Inhibitory effects of glycopyrronium, formoterol, and budesonide on Coronavirus Hcov-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020;58:155–68. 10.1016/j.resinv.2019.12.005 PubMed DOI PMC

Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J 2020;55:2001009. 10.1183/13993003.01009-2020 PubMed DOI PMC

Ramakrishnan S, Nicolau DV, Langford B, et al. . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021;9:763–72. 10.1016/S2213-2600(21)00160-0 PubMed DOI PMC

Laube BL, Janssens HM, de Jongh FHC, et al. . What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308–31. 10.1183/09031936.00166410 PubMed DOI

Rogliani P, Ora J, Puxeddu E, et al. . Adherence to COPD treatment: myth and reality. Respir Med 2017;129:117–23. 10.1016/j.rmed.2017.06.007 PubMed DOI

Vytrisalova M, Hendrychova T, Touskova T, et al. . Breathing out completely before inhalation: the most problematic step in application technique in patients with non-mild chronic obstructive pulmonary disease. Front Pharmacol 2019;10:241. 10.3389/fphar.2019.00241 PubMed DOI PMC

Plaza V, Giner J, Rodrigo GJ, et al. . Errors in the use of inhalers by health care professionals: a systematic review. J Allergy Clin Immunol Pract 2018;6:987–95. 10.1016/j.jaip.2017.12.032 PubMed DOI

Capstick TGD, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med 2012;6:91–101; 10.1586/ers.11.89 PubMed DOI

Luczak-Wozniak K, Dabrowska M, Domagala I, et al. . Mishandling of pMDI and DPI Inhalers in asthma and COPD - repetitive and non-repetitive errors. Pulm Pharmacol Ther 2018;51:65–72. 10.1016/j.pupt.2018.06.002 PubMed DOI

Usmani OS, Lavorini F, Marshall J, et al. . Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res 2018;19:10. 10.1186/s12931-017-0710-y PubMed DOI PMC

NICE . Inhaled corticosteroid doses for NICE’s asthma guideline. 2018.

Poudel AN, Zhu S, Cooper N, et al. . Impact of covid-19 on health-related quality of life of patients: a structured review. PLoS ONE 2021;16:e0259164. 10.1371/journal.pone.0259164 PubMed DOI PMC

Devlin NJ, Shah KK, Feng Y, et al. . Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2018;27:7–22. 10.1002/hec.3564 PubMed DOI PMC

Yu L-M, Bafadhel M, Dorward J, et al. . Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021;398:843–55. 10.1016/S0140-6736(21)01744-X PubMed DOI PMC

Griesel M, Wagner C, Mikolajewska A, et al. . Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2022;3:CD015125. 10.1002/14651858.CD015125 PubMed DOI PMC

Matsuyama S, Kawase M, Nao N, et al. . The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol 2020;95:e01648-20. 10.1128/JVI.01648-20 PubMed DOI PMC

Li H, Yan B, Gao R, et al. . Effectiveness of corticosteroids to treat severe COVID-19: a systematic review and meta-analysis of prospective studies. Int Immunopharmacol 2021;100:108121. 10.1016/j.intimp.2021.108121 PubMed DOI PMC

Myles P, Nguyen-Van-Tam JS, Semple MG, et al. . Differences between asthmatics and nonasthmatics hospitalised with influenza a infection. Eur Respir J 2013;41:824–31. 10.1183/09031936.00015512 PubMed DOI PMC

Grasselli G, Zangrillo A, Zanella A, et al. . Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to Icus of the Lombardy region. JAMA 2020;323:1574–81. 10.1001/jama.2020.5394 PubMed DOI PMC

Richardson S, Hirsch JS, Narasimhan M, et al. . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052–9. 10.1001/jama.2020.6775 PubMed DOI PMC

Halpin DMG, Faner R, Sibila O, et al. . Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection. Lancet Respir Med 2020;8:436–8. 10.1016/S2213-2600(20)30167-3 PubMed DOI PMC

Panettieri RA, Carson J, Horton D, et al. . Asthma and COVID: what are the important questions? J Allergy Clin Immunol Pract 2020;8:2487–8. 10.1016/j.jaip.2020.06.008 PubMed DOI PMC

Peters MC, Fahy JV. COVID-19–related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020;202:1744–6. 10.1164/rccm.v202erratum7 PubMed DOI PMC